ARTICLE | Distillery Techniques
Biomarkers
April 25, 2017 4:19 PM UTC
T cell clonality or DNA copy number loss burden could help predict therapeutic response to sequential anti-CTLA-4 and anti-PD1 therapies. In melanoma patients treated with an anti-CTLA-4 mAb followed ...
BCIQ Company Profiles